Last reviewed · How we verify
Short Tirofiban
Short Tirofiban is a Small molecule drug developed by Medicure. It is currently in Phase 2 development. Also known as: Aggrastat.
Tirofiban is a small molecule inhibitor of the Integrin alpha-IIb/beta-3, classified as an INHIBITOR drug class. It is used to treat conditions such as myocardial infarction, acute coronary syndromes, unstable angina, and STEMI.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Short Tirofiban |
|---|---|
| Also known as | Aggrastat |
| Sponsor | Medicure |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention (PHASE2)
- Effect of Upstream High Bolus Dose of Tirofiban in Primary PCI for the Patients With STEMI on Short Term Outcome (PHASE1, PHASE2)
- Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Short Tirofiban CI brief — competitive landscape report
- Short Tirofiban updates RSS · CI watch RSS
- Medicure portfolio CI
Frequently asked questions about Short Tirofiban
What is Short Tirofiban?
Who makes Short Tirofiban?
Is Short Tirofiban also known as anything else?
What development phase is Short Tirofiban in?
Related
- Manufacturer: Medicure — full pipeline
- Also known as: Aggrastat
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing